Pharmafile Logo

Founders4Schools

- PMLiVE

NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia

The recommendation makes Scemblix the first treatment in its class to be authorised in Britain

- PMLiVE

Novartis UK launches local charity partnerships to support social mobility pledges

The company has partnered with the Social Mobility Foundation, Founders4Schools and OnSide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links